Peptide Atlas · Protein

Albiglutide

Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78).

established

provisional
2 citations
0 discussions
0 followers
Eperzan
GSK716155
Syncria
Tanzeum

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Albiglutide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Liraglutide lowered HbA1c more than albiglutide in a head-to-head phase 3 trial (HARMONY 7)	established	pmid 24703047
Albiglutide reduced major cardiovascular events against placebo in type 2 diabetes with cardiovascular disease (Harmony Outcomes)	established	pmid 30291013

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.